{
    "info": {
        "nct_id": "NCT06043713",
        "official_title": "Phase I Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors in Participants With Metastatic Solid Tumors With KRAS G12V Mutations",
        "inclusion_criteria": "* LEUKAPHERESIS: Diagnosis of metastatic solid tumor\n* LEUKAPHERESIS: Tissue confirmation of solid tumor. Confirmation of diagnosis must be or have been performed by internal pathology review of archival biopsy material or other pathologic material at Fred Hutch/University of Washington Cancer Consortium (UWMC)\n* LEUKAPHERESIS: HLA-A*11:01 confirmed through HLA typing at a clinically accredited laboratory\n* LEUKAPHERESIS: Previously documented KRASG12V mutation in tumor or plasma cell-free deoxyribonucleic acid (cfDNA) specimens by polymerase chain reaction (PCR) or next-generation sequencing (NGS) test\n* LEUKAPHERESIS: Measurable disease by RECIST 1.1 criteria: Participants must have measurable disease, defined as at least one target lesion that can be measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm, unless lymph node in which case short axis must be ≥ 15 mm. Baseline imaging (for example, diagnostic CT chest/abdomen/pelvis and imaging of the affected extremity as appropriate), brain imaging (MRI or CT scan) if clinically indicated, must be obtained within 8 weeks of the first planned T cell infusion. MRI can be substituted for CT in participants unable to have CT contrast\n* LEUKAPHERESIS: Participants must be willing to undergo tumor biopsy for research purposes if safe and feasible at baseline (prior to first T cell infusion), 2-3 weeks after the first T cell infusion, and approximately 2 weeks +/- 1 week after the 2nd infusion (if applicable), if safe and feasible (these time windows may vary due to manufacturing or clinical reasons). Should there be no tumor tissue that is accessible for biopsy, subjects will still be considered for participation, at the discretion of the investigator. Similarly, should an investigator determine that a biopsy cannot be performed safely for clinical reasons, biopsies may be cancelled or rescheduled. Patients can also refuse biopsies at any time after enrollment\n* LEUKAPHERESIS: Participants must be at least two weeks or five half-lives (for small molecules) from last systemic treatment: At least 2 weeks must have passed since any: immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, vaccines), or chemotherapy cancer treatment. At least five half-lives must have passed from treatment with small molecules or other investigational agents. There is no washout period for radiation, so long as radiated lesion is not the lesion being evaluated for RECIST measurements on the protocol. Bisphosphonates and denosumab are permitted\n* LEUKAPHERESIS: Participants must have progressed on or be intolerant to at least one lines of prior therapy including any targeted therapies indicated for subjects with each of the tumor types eligible to enroll, as applicable\n* LEUKAPHERESIS: Patients with solid tumors harboring targetable molecular alterations including but not limited to EGFR mutations, ALK, ROS, NTRK fusions, microsatellite instability (MSI)-high, tumor mutational burden (TMB) high, BRAF v600 mutations, HER2 amplifications, must have been treated or refused treatment with applicable targeted therapies, as applicable\n* LEUKAPHERESIS: Fertile male and female participants must be willing to use an effective contraceptive method before, during, and for at least 4 months after the last A11KRASG12V-TCR infusion\n* LEUKAPHERESIS: 18 years or older at the time of enrollment\n* LEUKAPHERESIS: Capable of understanding and providing a written informed consent\n* LEUKAPHERESIS: Eastern Cooperative Oncology Group (ECOG) performance status of =< 1\n\n  * No uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days\n* LEUKAPHERESIS: No uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days\n* LEUKAPHERESIS: Renal: Creatinine clearance >= 50 ml/min by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) or 24-hour urine clearance\n* LEUKAPHERESIS: Hepatic: Total bilirubin < 2.0 mg/dL\n* LEUKAPHERESIS: Hepatic: Aspartate transferase (AST) and alanine transaminase (ALT) < 5x upper limit of normal (ULN)\n* LEUKAPHERESIS: Hepatic: Participants with suspected Gilbert syndrome may be included if total bilirubin (Bili) > 3 mg/dL but no other evidence of hepatic dysfunction\n* LEUKAPHERESIS: Cardiac: Participants 60 years of age or older are required to have left ventricular ejection fraction (LVEF) evaluation performed within 60 days prior to enrollment. LVEF may be established with echocardiogram or MUGA scan, and LVEF must be >= 35%. Cardiac evaluation for other participants is at the discretion of the treating physician\n* LEUKAPHERESIS: Hematologic: Absolute neutrophil count (ANC) >= 1000 cells/ mm^3\n* LEUKAPHERESIS: Nutrition: Albumin >= 3 g/dL\n* START OF TREATMENT: Measurable disease by RECIST 1.1 criteria: Participants must have measurable disease, defined as at least one target lesion that can be measured in at least one dimension (longest diameter to be recorded) as >= 10 mm, unless lymph node in which case short axis must be >= 15 mm. Baseline imaging (for example, diagnostic CT chest/abdomen/pelvis and imaging of the affected extremity as appropriate), brain imaging (MRI or CT scan) must be obtained within 8 weeks of the first planned T cell infusion. MRI can be substituted for CT in participants unable to have CT contrast\n* START OF TREATMENT: Participants must be willing to undergo tumor biopsy for research purposes if safe and feasible at baseline (prior to first T cell infusion), 2-3 weeks after the first T cell infusion, and approximately 2 weeks +/- 1 week after the 2nd infusion (if applicable), if safe and feasible (these windows may vary due to manufacturing or clinical reasons). Should there be no tumor tissue that is accessible for biopsy, subjects will still be considered for participation, at discretion of the investigator. Similarly, should an investigator determine that a biopsy cannot be performed safely for clinical reasons, biopsies may be cancelled or rescheduled\n* START OF TREATMENT: Participants must be at least two weeks from last systemic treatment: At least 2 weeks must have passed since any: immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, vaccines), or chemotherapy cancer treatment. At least five half-lives must have passed from treatment with small molecules or other investigational agents. There is no washout period for radiation, so long as radiated lesion is not the lesion being evaluated for RECIST measurements on the protocol. Bisphosphonates and denosumab are permitted\n* START OF TREATMENT: ECOG performance status of =< 1\n* START OF TREATMENT: Renal: Creatinine clearance >= 50 ml/min by CKD-EPI or 24-hour urine clearance\n\n  * Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement\n* START OF TREATMENT: Hepatic: Total bilirubin < 2.0 mg/dL\n\n  * Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement\n* START OF TREATMENT: AST and ALT < 5x upper limit of normal (ULN)\n* START OF TREATMENT: Participants with suspected Gilbert syndrome may be included if total Bili > 3 mg/dl but no other evidence of hepatic dysfunction\n* START OF TREATMENT: Pulmonary: =< grade 1 dyspnea and oxygen saturation of arterial blood (SaO2) >= 92% on ambient air. If pulmonary function tests (PFTs) are performed based on the clinical judgement of the treating physician, participants with forced expiratory volume in the first second (FEVI) >= 50% of predicted and diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected) >= 40% of predicted will be eligible\n\n  * Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement\n* START OF TREATMENT: Hematologic: ANC >= 1000 cells/ mm^3\n\n  * Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement\n* START OF TREATMENT: Nutrition: Albumin >= 3 g/dL\n\n  * Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement\n* START OF TREATMENT: Participants with a history of chronic obstructive pulmonary disease (COPD), emphysema, or greater than 30 pack year smoking history should undergo PFTs and meet the following criteria:\n\n  * FEVI >= 50% of predicted and DLCO (corrected) >= 40% of predicted will be eligible\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* LEUKAPHERESIS: Prior solid organ transplant or allogeneic hematopoietic stem cell transplant: Kidney transplant participants will be considered on a case-by-case basis requiring discussion with PI. If the participant has had a kidney transplant, participant must have dialysis access, dialysis plan, supportive nephrologist, willingness to stop transplant immunosuppression, and express understanding that rejection is possible outcome. Dialysis or costs related to transplant kidney will not be supported by the study. Participants having had any other solid organ transplants will be excluded, as will those with any history of allogeneic hematopoietic stem cell transplant\n* START OF TREATMENT: Pregnancy, breastfeeding, or expecting to conceive or father children for the duration of the trial through 4 months after last T-cell infusion. Participants of childbearing potential must have a negative serum pregnancy test within the 2 weeks (14 days) preceding T cell infusion. Childbearing potential is defined as women who have not been surgically sterilized and who are not post-menopausal (free of menses for at least 1 year)\n* START OF TREATMENT: Active autoimmune disease: Participants with active autoimmune disease requiring immunosuppressive therapy are excluded. Case by case exemptions are possible with approval by PI\n* START OF TREATMENT: Corticosteroid therapy at a dose equivalent of > 0.5 mg/kg of prednisone per day. The following treatments are permitted: intranasal, inhaled, topical, or local steroid applications; systemic corticosteroids at physiologic doses equivalent to no more than > 0.5 mg/kg/day prednisone; steroids as premedication for contrast dye allergy\n* START OF TREATMENT: Concurrent use of other investigational anti-cancer agents\n* START OF TREATMENT: Active uncontrolled infection: Human immunodeficiency virus (HIV) positive participants on highly active antiretroviral therapy (HAART) with a CD4 count > 500 cells/mm^3 are considered controlled, as are individuals with a history of hepatitis C who have successfully completed antiviral therapy with an undetectable viral load, and those with hepatitis B who have hepatitis well controlled on medication\n* START OF TREATMENT: Uncontrolled concurrent illness: Participants may not have uncontrolled or concurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* START OF TREATMENT: Untreated brain metastases: Participants with small asymptomatic brain metastases (< 1 cm) or those with brain metastases previously treated and controlled with surgery or radiotherapy will be considered for inclusion at discretion of PI, so long as all other eligibility criteria are met\n* START OF TREATMENT: Active treatment for prior immune related adverse event to any immunotherapy: Participants receiving ongoing treatment for prior serious immune-related adverse events are excluded, with exception of hormone supplementation or corticosteroid therapy at equivalent of up to 0.5mg/kg/day prednisone per day, unless otherwise approved by PI\n* START OF TREATMENT: Other medical, social, or psychiatric factor that interferes with medical appropriateness and/or ability to comply with study, as determined by the PI\n* START OF TREATMENT: Known allergic reactions to any of the components of study treatments\n* START OF TREATMENT: Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* LEUKAPHERESIS: Measurable disease by RECIST 1.1 criteria: Participants must have measurable disease, defined as at least one target lesion that can be measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm, unless lymph node in which case short axis must be ≥ 15 mm. Baseline imaging (for example, diagnostic CT chest/abdomen/pelvis and imaging of the affected extremity as appropriate), brain imaging (MRI or CT scan) if clinically indicated, must be obtained within 8 weeks of the first planned T cell infusion. MRI can be substituted for CT in participants unable to have CT contrast",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease by RECIST 1.1 criteria",
                    "criterion": "measurable disease by RECIST 1.1",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one target lesion that can be measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm",
                    "criterion": "target lesion size (non-lymph node)",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless lymph node in which case short axis must be ≥ 15 mm",
                    "criterion": "lymph node short axis size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "mm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Baseline imaging (for example, diagnostic CT chest/abdomen/pelvis and imaging of the affected extremity as appropriate), brain imaging (MRI or CT scan) if clinically indicated, must be obtained within 8 weeks of the first planned T cell infusion",
                    "criterion": "baseline imaging",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 8 weeks of the first planned T cell infusion"
                        }
                    ]
                },
                {
                    "exact_snippets": "brain imaging (MRI or CT scan) if clinically indicated",
                    "criterion": "brain imaging if clinically indicated",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "MRI can be substituted for CT in participants unable to have CT contrast",
                    "criterion": "MRI substitution for CT contrast",
                    "requirements": [
                        {
                            "requirement_type": "substitution",
                            "expected_value": "MRI for CT if unable to have CT contrast"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Nutrition: Albumin >= 3 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Albumin >= 3 g/dL",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Eastern Cooperative Oncology Group (ECOG) performance status of =< 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of =< 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Participants with a history of chronic obstructive pulmonary disease (COPD), emphysema, or greater than 30 pack year smoking history should undergo PFTs and meet the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "history of chronic obstructive pulmonary disease (COPD)",
                    "criterion": "chronic obstructive pulmonary disease (COPD) history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "emphysema",
                    "criterion": "emphysema history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "greater than 30 pack year smoking history",
                    "criterion": "smoking history (pack years)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "pack years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Hematologic: ANC >= 1000 cells/ mm^3",
            "criterions": [
                {
                    "exact_snippets": "ANC >= 1000 cells/ mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "cells/mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Capable of understanding and providing a written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Capable of understanding and providing a written informed consent",
                    "criterion": "informed consent capability",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Participants must be willing to undergo tumor biopsy for research purposes if safe and feasible at baseline (prior to first T cell infusion), 2-3 weeks after the first T cell infusion, and approximately 2 weeks +/- 1 week after the 2nd infusion (if applicable), if safe and feasible (these windows may vary due to manufacturing or clinical reasons). Should there be no tumor tissue that is accessible for biopsy, subjects will still be considered for participation, at discretion of the investigator. Similarly, should an investigator determine that a biopsy cannot be performed safely for clinical reasons, biopsies may be cancelled or rescheduled",
            "criterions": [
                {
                    "exact_snippets": "Participants must be willing to undergo tumor biopsy for research purposes if safe and feasible at baseline (prior to first T cell infusion), 2-3 weeks after the first T cell infusion, and approximately 2 weeks +/- 1 week after the 2nd infusion (if applicable), if safe and feasible",
                    "criterion": "willingness to undergo tumor biopsy",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "baseline (prior to first T cell infusion)",
                                "2-3 weeks after the first T cell infusion",
                                "approximately 2 weeks +/- 1 week after the 2nd infusion (if applicable)"
                            ]
                        },
                        {
                            "requirement_type": "safety and feasibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Should there be no tumor tissue that is accessible for biopsy, subjects will still be considered for participation, at discretion of the investigator",
                    "criterion": "tumor tissue accessibility for biopsy",
                    "requirements": [
                        {
                            "requirement_type": "accessibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "should an investigator determine that a biopsy cannot be performed safely for clinical reasons, biopsies may be cancelled or rescheduled",
                    "criterion": "biopsy safety for clinical reasons",
                    "requirements": [
                        {
                            "requirement_type": "safety",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Nutrition: Albumin >= 3 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Albumin >= 3 g/dL",
                    "criterion": "albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement",
            "criterions": [
                {
                    "exact_snippets": "organ function affected by their organ-specific tumor involvement",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "not affected by organ-specific tumor involvement"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Hepatic: Total bilirubin < 2.0 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin < 2.0 mg/dL",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: HLA-A*11:01 confirmed through HLA typing at a clinically accredited laboratory",
            "criterions": [
                {
                    "exact_snippets": "HLA-A*11:01 confirmed through HLA typing at a clinically accredited laboratory",
                    "criterion": "HLA-A*11:01 allele",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation_method",
                            "expected_value": "HLA typing at a clinically accredited laboratory"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Renal: Creatinine clearance >= 50 ml/min by CKD-EPI or 24-hour urine clearance",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance >= 50 ml/min by CKD-EPI or 24-hour urine clearance",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "CKD-EPI",
                                "24-hour urine clearance"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Participants with suspected Gilbert syndrome may be included if total Bili > 3 mg/dl but no other evidence of hepatic dysfunction",
            "criterions": [
                {
                    "exact_snippets": "Participants with suspected Gilbert syndrome may be included",
                    "criterion": "suspected Gilbert syndrome",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "total Bili > 3 mg/dl",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "mg/dl"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no other evidence of hepatic dysfunction",
                    "criterion": "hepatic dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement",
            "criterions": [
                {
                    "exact_snippets": "organ function affected by their organ-specific tumor involvement",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "affected by organ-specific tumor involvement"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Participants must have progressed on or be intolerant to at least one lines of prior therapy including any targeted therapies indicated for subjects with each of the tumor types eligible to enroll, as applicable",
            "criterions": [
                {
                    "exact_snippets": "Participants must have progressed on or be intolerant to at least one lines of prior therapy",
                    "criterion": "prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapies with progression or intolerance",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including any targeted therapies indicated for subjects with each of the tumor types eligible to enroll, as applicable",
                    "criterion": "targeted therapies indicated for tumor type",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure or intolerance",
                            "expected_value": "must have received or been intolerant to any targeted therapies indicated for their tumor type"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: No uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days",
            "criterions": [
                {
                    "exact_snippets": "No uncontrolled pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "no uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "No uncontrolled ... pericardial effusion",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "no uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "No uncontrolled ... ascites requiring repeated drainage more than once every 28 days",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "no uncontrolled"
                        },
                        {
                            "requirement_type": "drainage frequency",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "per 28 days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Measurable disease by RECIST 1.1 criteria: Participants must have measurable disease, defined as at least one target lesion that can be measured in at least one dimension (longest diameter to be recorded) as >= 10 mm, unless lymph node in which case short axis must be >= 15 mm. Baseline imaging (for example, diagnostic CT chest/abdomen/pelvis and imaging of the affected extremity as appropriate), brain imaging (MRI or CT scan) must be obtained within 8 weeks of the first planned T cell infusion. MRI can be substituted for CT in participants unable to have CT contrast",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease by RECIST 1.1 criteria",
                    "criterion": "measurable disease (RECIST 1.1)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one target lesion that can be measured in at least one dimension (longest diameter to be recorded) as >= 10 mm",
                    "criterion": "target lesion size (non-lymph node)",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless lymph node in which case short axis must be >= 15 mm",
                    "criterion": "lymph node target lesion size",
                    "requirements": [
                        {
                            "requirement_type": "size (short axis)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "mm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Baseline imaging (for example, diagnostic CT chest/abdomen/pelvis and imaging of the affected extremity as appropriate), brain imaging (MRI or CT scan) must be obtained within 8 weeks of the first planned T cell infusion",
                    "criterion": "baseline imaging",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks before first planned T cell infusion"
                            }
                        },
                        {
                            "requirement_type": "modalities",
                            "expected_value": [
                                "CT chest/abdomen/pelvis",
                                "imaging of affected extremity as appropriate",
                                "brain imaging (MRI or CT scan)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "MRI can be substituted for CT in participants unable to have CT contrast",
                    "criterion": "MRI substitution for CT",
                    "requirements": [
                        {
                            "requirement_type": "substitution allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Hematologic: Absolute neutrophil count (ANC) >= 1000 cells/ mm^3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1000 cells/ mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "cells/mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement",
            "criterions": [
                {
                    "exact_snippets": "organ function affected by their organ-specific tumor involvement",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "affected by organ-specific tumor involvement"
                        }
                    ]
                },
                {
                    "exact_snippets": "Exceptions may be at the discretion of the PI",
                    "criterion": "PI discretion for exceptions",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days",
            "criterions": [
                {
                    "exact_snippets": "No uncontrolled pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "No uncontrolled ... pericardial effusion",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "No uncontrolled ... ascites requiring repeated drainage more than once every 28 days",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        },
                        {
                            "requirement_type": "drainage frequency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "per 28 days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Participants must be willing to undergo tumor biopsy for research purposes if safe and feasible at baseline (prior to first T cell infusion), 2-3 weeks after the first T cell infusion, and approximately 2 weeks +/- 1 week after the 2nd infusion (if applicable), if safe and feasible (these time windows may vary due to manufacturing or clinical reasons). Should there be no tumor tissue that is accessible for biopsy, subjects will still be considered for participation, at the discretion of the investigator. Similarly, should an investigator determine that a biopsy cannot be performed safely for clinical reasons, biopsies may be cancelled or rescheduled. Patients can also refuse biopsies at any time after enrollment",
            "criterions": [
                {
                    "exact_snippets": "Participants must be willing to undergo tumor biopsy for research purposes if safe and feasible at baseline (prior to first T cell infusion), 2-3 weeks after the first T cell infusion, and approximately 2 weeks +/- 1 week after the 2nd infusion (if applicable), if safe and feasible",
                    "criterion": "willingness to undergo tumor biopsy",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "baseline (prior to first T cell infusion)",
                                "2-3 weeks after the first T cell infusion",
                                "approximately 2 weeks +/- 1 week after the 2nd infusion (if applicable)"
                            ]
                        },
                        {
                            "requirement_type": "safety and feasibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Should there be no tumor tissue that is accessible for biopsy, subjects will still be considered for participation, at the discretion of the investigator.",
                    "criterion": "tumor tissue accessibility for biopsy",
                    "requirements": [
                        {
                            "requirement_type": "accessibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "should an investigator determine that a biopsy cannot be performed safely for clinical reasons, biopsies may be cancelled or rescheduled.",
                    "criterion": "biopsy safety for clinical reasons",
                    "requirements": [
                        {
                            "requirement_type": "safety",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients can also refuse biopsies at any time after enrollment",
                    "criterion": "patient consent for biopsy",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Diagnosis of metastatic solid tumor",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of metastatic solid tumor",
                    "criterion": "metastatic solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Renal: Creatinine clearance >= 50 ml/min by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) or 24-hour urine clearance",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance >= 50 ml/min by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) or 24-hour urine clearance",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)",
                                "24-hour urine clearance"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement",
            "criterions": [
                {
                    "exact_snippets": "organ function affected by their organ-specific tumor involvement",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "affected by organ-specific tumor involvement"
                        }
                    ]
                },
                {
                    "exact_snippets": "Exceptions may be at the discretion of the PI",
                    "criterion": "PI discretion for exceptions",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: AST and ALT < 5x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "AST and ALT < 5x upper limit of normal (ULN)",
                    "criterion": "AST (aspartate aminotransferase) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST and ALT < 5x upper limit of normal (ULN)",
                    "criterion": "ALT (alanine aminotransferase) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement",
            "criterions": [
                {
                    "exact_snippets": "organ function affected by their organ-specific tumor involvement",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "affected by organ-specific tumor involvement"
                        }
                    ]
                },
                {
                    "exact_snippets": "Exceptions may be at the discretion of the PI",
                    "criterion": "PI discretion for exceptions",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Patients with solid tumors harboring targetable molecular alterations including but not limited to EGFR mutations, ALK, ROS, NTRK fusions, microsatellite instability (MSI)-high, tumor mutational burden (TMB) high, BRAF v600 mutations, HER2 amplifications, must have been treated or refused treatment with applicable targeted therapies, as applicable",
            "criterions": [
                {
                    "exact_snippets": "solid tumors harboring targetable molecular alterations including but not limited to EGFR mutations, ALK, ROS, NTRK fusions, microsatellite instability (MSI)-high, tumor mutational burden (TMB) high, BRAF v600 mutations, HER2 amplifications",
                    "criterion": "targetable molecular alterations in solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "alteration_type",
                            "expected_value": [
                                "EGFR mutations",
                                "ALK",
                                "ROS",
                                "NTRK fusions",
                                "microsatellite instability (MSI)-high",
                                "tumor mutational burden (TMB) high",
                                "BRAF v600 mutations",
                                "HER2 amplifications"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "must have been treated or refused treatment with applicable targeted therapies, as applicable",
                    "criterion": "treatment with applicable targeted therapies",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "treated",
                                "refused treatment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: ECOG performance status of =< 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of =< 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Pulmonary: =< grade 1 dyspnea and oxygen saturation of arterial blood (SaO2) >= 92% on ambient air. If pulmonary function tests (PFTs) are performed based on the clinical judgement of the treating physician, participants with forced expiratory volume in the first second (FEVI) >= 50% of predicted and diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected) >= 40% of predicted will be eligible",
            "criterions": [
                {
                    "exact_snippets": "=< grade 1 dyspnea",
                    "criterion": "dyspnea",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "oxygen saturation of arterial blood (SaO2) >= 92% on ambient air",
                    "criterion": "oxygen saturation of arterial blood (SaO2)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "forced expiratory volume in the first second (FEVI) >= 50% of predicted",
                    "criterion": "forced expiratory volume in the first second (FEVI)",
                    "requirements": [
                        {
                            "requirement_type": "percentage of predicted",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected) >= 40% of predicted",
                    "criterion": "diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected)",
                    "requirements": [
                        {
                            "requirement_type": "percentage of predicted",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Tissue confirmation of solid tumor. Confirmation of diagnosis must be or have been performed by internal pathology review of archival biopsy material or other pathologic material at Fred Hutch/University of Washington Cancer Consortium (UWMC)",
            "criterions": [
                {
                    "exact_snippets": "Tissue confirmation of solid tumor",
                    "criterion": "solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "confirmation by tissue",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Confirmation of diagnosis must be or have been performed by internal pathology review of archival biopsy material or other pathologic material at Fred Hutch/University of Washington Cancer Consortium (UWMC)",
                    "criterion": "diagnosis confirmation by internal pathology review at Fred Hutch/UWMC",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "internal pathology review"
                        },
                        {
                            "requirement_type": "institution",
                            "expected_value": "Fred Hutch/University of Washington Cancer Consortium (UWMC)"
                        },
                        {
                            "requirement_type": "material type",
                            "expected_value": [
                                "archival biopsy material",
                                "other pathologic material"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Participants must be at least two weeks or five half-lives (for small molecules) from last systemic treatment: At least 2 weeks must have passed since any: immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, vaccines), or chemotherapy cancer treatment. At least five half-lives must have passed from treatment with small molecules or other investigational agents. There is no washout period for radiation, so long as radiated lesion is not the lesion being evaluated for RECIST measurements on the protocol. Bisphosphonates and denosumab are permitted",
            "criterions": [
                {
                    "exact_snippets": "Participants must be at least two weeks or five half-lives (for small molecules) from last systemic treatment",
                    "criterion": "time since last systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "minimum time since last systemic treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "At least 2 weeks must have passed since any: immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, vaccines), or chemotherapy cancer treatment.",
                    "criterion": "time since last immunotherapy or chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "minimum time since last immunotherapy or chemotherapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "At least five half-lives must have passed from treatment with small molecules or other investigational agents.",
                    "criterion": "time since last small molecule or investigational agent treatment",
                    "requirements": [
                        {
                            "requirement_type": "minimum time since last small molecule or investigational agent treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "There is no washout period for radiation, so long as radiated lesion is not the lesion being evaluated for RECIST measurements on the protocol.",
                    "criterion": "radiation to lesion being evaluated for RECIST",
                    "requirements": [
                        {
                            "requirement_type": "radiation to RECIST-evaluated lesion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Bisphosphonates and denosumab are permitted",
                    "criterion": "bisphosphonate or denosumab use",
                    "requirements": [
                        {
                            "requirement_type": "use permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Fertile male and female participants must be willing to use an effective contraceptive method before, during, and for at least 4 months after the last A11KRASG12V-TCR infusion",
            "criterions": [
                {
                    "exact_snippets": "Fertile male and female participants must be willing to use an effective contraceptive method before, during, and for at least 4 months after the last A11KRASG12V-TCR infusion",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "before",
                                "during",
                                "for at least 4 months after the last A11KRASG12V-TCR infusion"
                            ]
                        },
                        {
                            "requirement_type": "method",
                            "expected_value": "effective contraceptive method"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* FEVI >= 50% of predicted and DLCO (corrected) >= 40% of predicted will be eligible",
            "criterions": [
                {
                    "exact_snippets": "FEVI >= 50% of predicted",
                    "criterion": "FEVI",
                    "requirements": [
                        {
                            "requirement_type": "percentage of predicted value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "DLCO (corrected) >= 40% of predicted",
                    "criterion": "DLCO (corrected)",
                    "requirements": [
                        {
                            "requirement_type": "percentage of predicted value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: 18 years or older at the time of enrollment",
            "criterions": [
                {
                    "exact_snippets": "18 years or older at the time of enrollment",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age at enrollment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Previously documented KRASG12V mutation in tumor or plasma cell-free deoxyribonucleic acid (cfDNA) specimens by polymerase chain reaction (PCR) or next-generation sequencing (NGS) test",
            "criterions": [
                {
                    "exact_snippets": "Previously documented KRASG12V mutation in tumor or plasma cell-free deoxyribonucleic acid (cfDNA) specimens",
                    "criterion": "KRASG12V mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "specimen_type",
                            "expected_value": [
                                "tumor",
                                "plasma cell-free deoxyribonucleic acid (cfDNA)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "by polymerase chain reaction (PCR) or next-generation sequencing (NGS) test",
                    "criterion": "KRASG12V mutation detection method",
                    "requirements": [
                        {
                            "requirement_type": "detection_method",
                            "expected_value": [
                                "polymerase chain reaction (PCR)",
                                "next-generation sequencing (NGS)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Hepatic: Total bilirubin < 2.0 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Hepatic: Total bilirubin < 2.0 mg/dL",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Cardiac: Participants 60 years of age or older are required to have left ventricular ejection fraction (LVEF) evaluation performed within 60 days prior to enrollment. LVEF may be established with echocardiogram or MUGA scan, and LVEF must be >= 35%. Cardiac evaluation for other participants is at the discretion of the treating physician",
            "criterions": [
                {
                    "exact_snippets": "Participants 60 years of age or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "left ventricular ejection fraction (LVEF) evaluation performed within 60 days prior to enrollment",
                    "criterion": "LVEF evaluation timing",
                    "requirements": [
                        {
                            "requirement_type": "performed_within",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days prior to enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "LVEF may be established with echocardiogram or MUGA scan",
                    "criterion": "LVEF assessment method",
                    "requirements": [
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "echocardiogram",
                                "MUGA scan"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "LVEF must be >= 35%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 35,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Hepatic: Participants with suspected Gilbert syndrome may be included if total bilirubin (Bili) > 3 mg/dL but no other evidence of hepatic dysfunction",
            "criterions": [
                {
                    "exact_snippets": "Participants with suspected Gilbert syndrome may be included if total bilirubin (Bili) > 3 mg/dL",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no other evidence of hepatic dysfunction",
                    "criterion": "hepatic dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Hepatic: Aspartate transferase (AST) and alanine transaminase (ALT) < 5x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate transferase (AST) ... < 5x upper limit of normal (ULN)",
                    "criterion": "aspartate transferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine transaminase (ALT) < 5x upper limit of normal (ULN)",
                    "criterion": "alanine transaminase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Participants must be at least two weeks from last systemic treatment: At least 2 weeks must have passed since any: immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, vaccines), or chemotherapy cancer treatment. At least five half-lives must have passed from treatment with small molecules or other investigational agents. There is no washout period for radiation, so long as radiated lesion is not the lesion being evaluated for RECIST measurements on the protocol. Bisphosphonates and denosumab are permitted",
            "criterions": [
                {
                    "exact_snippets": "Participants must be at least two weeks from last systemic treatment: At least 2 weeks must have passed since any: immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, vaccines), or chemotherapy cancer treatment.",
                    "criterion": "time since last systemic treatment (immunotherapy or chemotherapy)",
                    "requirements": [
                        {
                            "requirement_type": "minimum time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "At least five half-lives must have passed from treatment with small molecules or other investigational agents.",
                    "criterion": "time since last small molecule or investigational agent treatment",
                    "requirements": [
                        {
                            "requirement_type": "minimum time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "half-lives"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "There is no washout period for radiation, so long as radiated lesion is not the lesion being evaluated for RECIST measurements on the protocol.",
                    "criterion": "radiation to lesion being evaluated for RECIST",
                    "requirements": [
                        {
                            "requirement_type": "radiation to RECIST-evaluated lesion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Bisphosphonates and denosumab are permitted",
                    "criterion": "bisphosphonate or denosumab use",
                    "requirements": [
                        {
                            "requirement_type": "use permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* START OF TREATMENT: Untreated brain metastases: Participants with small asymptomatic brain metastases (< 1 cm) or those with brain metastases previously treated and controlled with surgery or radiotherapy will be considered for inclusion at discretion of PI, so long as all other eligibility criteria are met",
            "criterions": [
                {
                    "exact_snippets": "Untreated brain metastases: Participants with small asymptomatic brain metastases (< 1 cm)",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "symptoms",
                            "expected_value": "asymptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "brain metastases previously treated and controlled with surgery or radiotherapy",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment_history",
                            "expected_value": [
                                "surgery",
                                "radiotherapy"
                            ]
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Corticosteroid therapy at a dose equivalent of > 0.5 mg/kg of prednisone per day. The following treatments are permitted: intranasal, inhaled, topical, or local steroid applications; systemic corticosteroids at physiologic doses equivalent to no more than > 0.5 mg/kg/day prednisone; steroids as premedication for contrast dye allergy",
            "criterions": [
                {
                    "exact_snippets": "Corticosteroid therapy at a dose equivalent of > 0.5 mg/kg of prednisone per day",
                    "criterion": "corticosteroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 0.5,
                                "unit": "mg/kg/day prednisone"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "The following treatments are permitted: intranasal, inhaled, topical, or local steroid applications",
                    "criterion": "steroid application route",
                    "requirements": [
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "intranasal",
                                "inhaled",
                                "topical",
                                "local"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic corticosteroids at physiologic doses equivalent to no more than > 0.5 mg/kg/day prednisone",
                    "criterion": "systemic corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 0.5,
                                "unit": "mg/kg/day prednisone"
                            }
                        },
                        {
                            "requirement_type": "physiologic dose",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "steroids as premedication for contrast dye allergy",
                    "criterion": "steroid use as premedication for contrast dye allergy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": "premedication for contrast dye allergy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Uncontrolled concurrent illness: Participants may not have uncontrolled or concurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled or concurrent illness",
                    "criterion": "uncontrolled or concurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure",
                    "criterion": "symptomatic congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "unstable angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Active treatment for prior immune related adverse event to any immunotherapy: Participants receiving ongoing treatment for prior serious immune-related adverse events are excluded, with exception of hormone supplementation or corticosteroid therapy at equivalent of up to 0.5mg/kg/day prednisone per day, unless otherwise approved by PI",
            "criterions": [
                {
                    "exact_snippets": "Active treatment for prior immune related adverse event to any immunotherapy: Participants receiving ongoing treatment for prior serious immune-related adverse events are excluded",
                    "criterion": "ongoing treatment for prior serious immune-related adverse events",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "with exception of hormone supplementation or corticosteroid therapy at equivalent of up to 0.5mg/kg/day prednisone per day",
                    "criterion": "corticosteroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 0.5,
                                "unit": "mg/kg/day prednisone"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with exception of hormone supplementation",
                    "criterion": "hormone supplementation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "pericardial effusion",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "ascites requiring repeated drainage more than once every 28 days",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "drainage frequency",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "per 28 days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Active uncontrolled infection: Human immunodeficiency virus (HIV) positive participants on highly active antiretroviral therapy (HAART) with a CD4 count > 500 cells/mm^3 are considered controlled, as are individuals with a history of hepatitis C who have successfully completed antiviral therapy with an undetectable viral load, and those with hepatitis B who have hepatitis well controlled on medication",
            "criterions": [
                {
                    "exact_snippets": "Active uncontrolled infection",
                    "criterion": "infection status",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "no active uncontrolled infection"
                        }
                    ]
                },
                {
                    "exact_snippets": "Human immunodeficiency virus (HIV) positive participants on highly active antiretroviral therapy (HAART) with a CD4 count > 500 cells/mm^3 are considered controlled",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "HIV status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "therapy",
                            "expected_value": "on HAART"
                        },
                        {
                            "requirement_type": "CD4 count",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "cells/mm^3"
                            }
                        },
                        {
                            "requirement_type": "infection control",
                            "expected_value": "controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of hepatitis C who have successfully completed antiviral therapy with an undetectable viral load",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "antiviral therapy completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "viral load",
                            "expected_value": "undetectable"
                        },
                        {
                            "requirement_type": "infection control",
                            "expected_value": "controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B who have hepatitis well controlled on medication",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "infection status",
                            "expected_value": "well controlled"
                        },
                        {
                            "requirement_type": "medication",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Known allergic reactions to any of the components of study treatments",
            "criterions": [
                {
                    "exact_snippets": "Known allergic reactions to any of the components of study treatments",
                    "criterion": "allergic reactions to components of study treatments",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LEUKAPHERESIS: Prior solid organ transplant or allogeneic hematopoietic stem cell transplant: Kidney transplant participants will be considered on a case-by-case basis requiring discussion with PI. If the participant has had a kidney transplant, participant must have dialysis access, dialysis plan, supportive nephrologist, willingness to stop transplant immunosuppression, and express understanding that rejection is possible outcome. Dialysis or costs related to transplant kidney will not be supported by the study. Participants having had any other solid organ transplants will be excluded, as will those with any history of allogeneic hematopoietic stem cell transplant",
            "criterions": [
                {
                    "exact_snippets": "Prior solid organ transplant or allogeneic hematopoietic stem cell transplant",
                    "criterion": "history of solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior solid organ transplant or allogeneic hematopoietic stem cell transplant",
                    "criterion": "history of allogeneic hematopoietic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Kidney transplant participants will be considered on a case-by-case basis requiring discussion with PI",
                    "criterion": "kidney transplant",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": "case-by-case basis with PI discussion"
                        }
                    ]
                },
                {
                    "exact_snippets": "If the participant has had a kidney transplant, participant must have dialysis access",
                    "criterion": "dialysis access (for kidney transplant recipients)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If the participant has had a kidney transplant, participant must have ... dialysis plan",
                    "criterion": "dialysis plan (for kidney transplant recipients)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If the participant has had a kidney transplant, participant must have ... supportive nephrologist",
                    "criterion": "supportive nephrologist (for kidney transplant recipients)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If the participant has had a kidney transplant, participant must have ... willingness to stop transplant immunosuppression",
                    "criterion": "willingness to stop transplant immunosuppression (for kidney transplant recipients)",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If the participant has had a kidney transplant, participant must ... express understanding that rejection is possible outcome",
                    "criterion": "understanding of possible rejection (for kidney transplant recipients)",
                    "requirements": [
                        {
                            "requirement_type": "understanding",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants having had any other solid organ transplants will be excluded",
                    "criterion": "history of non-kidney solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "those with any history of allogeneic hematopoietic stem cell transplant",
                    "criterion": "history of allogeneic hematopoietic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Pregnancy, breastfeeding, or expecting to conceive or father children for the duration of the trial through 4 months after last T-cell infusion. Participants of childbearing potential must have a negative serum pregnancy test within the 2 weeks (14 days) preceding T cell infusion. Childbearing potential is defined as women who have not been surgically sterilized and who are not post-menopausal (free of menses for at least 1 year)",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to conceive or father children for the duration of the trial through 4 months after last T-cell infusion",
                    "criterion": "expecting to conceive or father children",
                    "requirements": [
                        {
                            "requirement_type": "time period",
                            "expected_value": "from start of trial through 4 months after last T-cell infusion"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants of childbearing potential must have a negative serum pregnancy test within the 2 weeks (14 days) preceding T cell infusion",
                    "criterion": "serum pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 2 weeks (14 days) preceding T cell infusion"
                        }
                    ]
                },
                {
                    "exact_snippets": "Childbearing potential is defined as women who have not been surgically sterilized and who are not post-menopausal (free of menses for at least 1 year)",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "women who have not been surgically sterilized and who are not post-menopausal (free of menses for at least 1 year)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Active autoimmune disease: Participants with active autoimmune disease requiring immunosuppressive therapy are excluded. Case by case exemptions are possible with approval by PI",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease: Participants with active autoimmune disease requiring immunosuppressive therapy are excluded.",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active autoimmune disease requiring immunosuppressive therapy are excluded.",
                    "criterion": "immunosuppressive therapy requirement for autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Other medical, social, or psychiatric factor that interferes with medical appropriateness and/or ability to comply with study, as determined by the PI",
            "criterions": [
                {
                    "exact_snippets": "Other medical, social, or psychiatric factor that interferes with medical appropriateness",
                    "criterion": "medical, social, or psychiatric factor interfering with medical appropriateness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact",
                            "expected_value": "interferes with medical appropriateness"
                        }
                    ]
                },
                {
                    "exact_snippets": "Other medical, social, or psychiatric factor that interferes with ... ability to comply with study",
                    "criterion": "medical, social, or psychiatric factor interfering with ability to comply with study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact",
                            "expected_value": "interferes with ability to comply with study"
                        }
                    ]
                },
                {
                    "exact_snippets": "as determined by the PI",
                    "criterion": "PI determination of eligibility",
                    "requirements": [
                        {
                            "requirement_type": "determination",
                            "expected_value": "as determined by the PI"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* START OF TREATMENT: Concurrent use of other investigational anti-cancer agents",
            "criterions": [
                {
                    "exact_snippets": "Concurrent use of other investigational anti-cancer agents",
                    "criterion": "use of investigational anti-cancer agents",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}